european end-to-end CDMO company, pharma services

Competition

Unlocking the Future of Therapeutics

Further is Closer - What if the right CDMO partner was closer than you thought? €500,000 in services to take your biologic further.

Entries for the competition are closed.

Applications will be reviewed in October, and the winner will be announced live at CPHI Frankfurt.

The deadline was 30 September 2025 at 23:59 CET.

Further → more

The winner will receive:

  • €500,000 in credit toward Mabion’s biologics CDMO services
  • End-to-end support including:
    • CMC development
    • Analytical and QC services
    • GMP drug substance or product manufacturing
    • Regulatory and project management guidance
  • NDA and proposal support for continued development
  • Visibility through press coverage and live announcement at CPHI Frankfurt

Mabion is awarding up to €500,000 in development services to support the advancement of one outstanding oncology-focused biologic — whether a novel therapeutic or a biosimilar aimed at expanding access to lifesaving oncology care.

The winning candidate will be selected by a panel of leading experts in oncology research and biomanufacturing, based on scientific merit, clinical potential and feasibility.

Biotech breakthroughs shouldn’t be delayed by funding gaps or infrastructure limits

Many lifesaving biopharmaceuticals are suffering from a slump in venture funding. Novel recombinant protein based therapeutics, but also biosimilars are needed to fill the gaps in unmet patient needs.

At Mabion, we know how hard it is to take an oncology biologic from concept to clinic, because we’ve done it ourselves. In today’s constrained funding environment, too many promising oncology candidates are stalling before they reach the clinic,  not because the science isn’t there, but because the infrastructure and resources aren’t.

That is why we are launching the “Unlocking the Future of Therapeutics” competition, with the ultimate goal of helping a deserving biotech team reach their next milestone faster and bring new hope to patients.

“Nothing in life is to be feared; it is only to be understood.“

Marie Skłodowska-Curie

Let’s grow together!

Meet the Expert Jury

Gestur Viðarsson, Prof.

Principal Investigator at Sanquin and Professor of Immunoglobulin Biotherapeutics at the Utrecht Institute for Pharmaceutical Sciences

Tadeusz Pietrucha, Prof.

Head of the Medical Biotechnology Department at Medical University of Łódź

Alicja Santos, PhD

Chief Executive Officer of Polonium Foundation

Julita Balcerek,
PhD, MBA, IPMA C

Chief Operating Officer of Mabion

FAQ

Mabion launched this contest to support promising oncology innovations that struggle to progress due to limited funding. With a history in drug development, Mabion seeks to help advance impactful therapies and promote Polish scientific excellence in medical research.
No. This is a competitive award. Up to the €500,000 in services will be awarded to one outstanding oncology therapeutic, selected by an expert panel.
Programs in preclinical to early clinical development are ideal. You should have a defined development plan and a need for CDMO support.
Yes. This is a global opportunity. The only requirement is that your therapeutic aligns with the oncology focus and development stage.
No. There’s no obligation to continue working with Mabion after the funded support, but we’d love to be your partner long-term.
The oncology pipeline is growing rapidly, yet funding remains a major barrier, especially for biologics. Mabion sees this as a critical moment to close that gap and accelerate novel therapies to patients.
Mabion offers end-to-end biologics development and manufacturing under one roof, reducing risks and speeding timelines. Operating from a cost-effective EU base, Mabion combines regulatory excellence, personalized project management, and integrated quality systems.
The winner receives €500,000 in service credits for biologics development, plus support with NDAs, proposal structuring, and business development. Mabion acts as a true partner, helping accelerate the project toward clinical readiness.
You do. Mabion will operate under strict confidentiality agreements and does not claim ownership of your therapeutic program.
The jury includes experts from academia and industry, chosen for their scientific and translational experience. They assess proposals based on impact, feasibility, and clinical potential, ensuring patient relevance and real-world viability.
Mabion aims to be a strategic CDMO partner by investing in high-potential biotech programs. This contest supports that goal by strengthening its oncology focus and building long-term collaborations.
Mabion hopes to speed up the development of new cancer treatments by equipping innovators with critical infrastructure. For biotech, it shows how CDMOs can drive innovation; for patients, it offers hope for faster access to breakthrough therapies.

“Further is closer. The breakthrough you need is closer than you think.“

Nigel Stapleton
VP of Business Development – Head of Europe at Mabion